Buy Dishman Pharma; target of Rs 285: Systematix
Systematix is bullish on Dishman Pharma has recommended buy rating on the stock with a target price of Rs 285 in its research report dated February 14, 2017.
Systematix's research report on Dishman Pharma
We have marginally reduced the estimates by 5%/6% for FY18e and FY19e on management’s guidance. Our revised estimates imply a revenue and profit CAGR of 7%/20% over FY16-19e. We have also reduced the target price to Rs 270 (Rs 285 earlier), which is 16x average EPS for FY18e and FY19e, though we maintain a Buy rating on the stock.
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.